替莫唑胺诱导的超突变与低级别IDH突变胶质瘤高级别转化后的远处复发及生存降低相关
本研究对82例初诊低级别IDH突变胶质瘤再手术患者的复发肿瘤测序,发现超突变与再手术时高级别病变相关(OR 12.0),在既往暴露于TMZ的复发LGG中57%于转化时检出超突变。间变性转化后超突变与更短生存相关(HR 3.4),且超突变肿瘤更易出现脑和脊柱不连续病灶。
要点
- TMZ暴露后的复发LGG高级别转化时超突变常见(57%)。
- 转化后超突变与更短生存独立相关(HR 3.4)。
- 超突变肿瘤更易发生脑和脊柱不连续病灶。
核心结论
- TMZ诱导的超突变在既往TMZ治疗的低级别IDH突变胶质瘤转化后常见,与更差预后及复发后不连续病灶相关。
研究设计与样本
- 对82例初诊低级别IDH突变胶质瘤再手术患者的复发肿瘤进行测序,分析超突变状态与复发级别及后续临床结局的相关性。
主要发现
- 超突变与再手术时高级别病变相关(OR 12.0,95%CI 2.5-115.5,P=.002)。
- 既往TMZ暴露的复发LGG中57%于转化时检出超突变。
- 间变性转化后,超突变与更短生存相关(HR 3.4,95%CI 1.2-9.9,P=.024),控制肿瘤级别、亚型、年龄和既往放疗。
- 超突变肿瘤更易出现脑和脊柱不连续病灶(P=.003)。
- 在LGG TMZ二期试验数据中,8年无转化生存率为53.8%(95%CI 42.8-69.2),分析的转化病例中61%为超突变。
临床怎么用
- 复发再手术时应评估超突变状态,辅助肿瘤分类与预后判断。
- 对TMZ暴露后转化的超突变患者,需警惕脑和脊柱不连续病灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-induced hypermutation. We aimed to determine the prevalence of TMZ-induced hypermutation at recurrence and prognostic implications. METHODS: We sequenced recurrent tumors from 82 patients with initially low-grade IDH-mutant gliomas who underwent reoperation and correlated hypermutation status with grade at recurrence and subsequent clinical outcomes. RESULTS: Hypermutation was associated with high-grade disease at the time of reoperation (OR 12.0 95% CI 2.5-115.5, P = .002) and was identified at transformation in 57% of recurrent LGGs previously exposed to TMZ. After anaplastic (grade III) transformation, hypermutation was associated with shorter survival on univariate and multivariate analysis (HR 3.4, 95% CI 1.2-9.9, P = .024), controlling for tumor grade, subtype, age, and prior radiotherapy. The effect of hypermutation on survival after transformation was validated in an independent, published dataset. Hypermutated (HM) tumors were more likely to develop discontiguous foci of disease in the brain and spine (P = .003). To estimate the overall incidence of high-grade transformation among low-grade IDH-mutant tumors, data from a phase II trial of TMZ for LGG were analyzed. Eight-year transformation-free survival was 53.8% (95% CI 42.8-69.2), and 61% of analyzed transformed cases were HM. CONCLUSIONS: TMZ-induced hypermutation is a common event in transformed LGG previously treated with TMZ and is associated with worse prognosis and development of discontiguous disease after recurrence. These findings impact tumor classification at recurrence, prognostication, and clinical trial design.
引用
- Yu Y, Villanueva-Meyer J, Grimmer MR, et al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol. 2021. PMID: 33823014. doi:10.1093/neuonc/noab081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。